Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Immunodeficiency Diseases (PID)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT07004803
What this trial is testing

Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency

Who this might be right for
Primary Immunodeficiency Diseases (PID)
Dr. Hatice Dönmez 31
Not applicableUnknownNCT03668288
What this trial is testing

Tolerance and Patients' Satisfaction With IGHy

Who this might be right for
Secondary or Primary Immunodeficiency
CHU de Reims 20
Not applicableLooking for participantsNCT04459689
What this trial is testing

COVID-19 in PID Survey

Who this might be right for
Primary Immune DeficiencyCOVID
Imagine Institute 200
Large-scale testing (Phase 3)Study completedNCT05755035
What this trial is testing

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Who this might be right for
Primary Immunodeficiency Diseases (PID)
Takeda 65
Not applicableNot Yet RecruitingNCT07189013
What this trial is testing

Assessing Patient Preference for Infusion Systems

Who this might be right for
Primary Immunodeficiencies (PID)Secondary Immunodeficiencies (SID)
KORU Medical Systems, Inc. 52
Large-scale testing (Phase 3)Study completedNCT05513586
What this trial is testing

Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Who this might be right for
Primary Immunodeficiency Diseases (PID)
Takeda 15
Not applicableUnknownNCT01617122
What this trial is testing

Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)

Who this might be right for
Primary Immune Deficiency Diseases
University of South Florida 200
Large-scale testing (Phase 3)Study completedNCT03277313
What this trial is testing

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Who this might be right for
Primary Immunodeficiency Diseases (PID)
Baxalta now part of Shire 44
Post-approval studies (Phase 4)Study completedNCT03116347
What this trial is testing

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Who this might be right for
Primary Immunodeficiency Diseases (PID)
Baxalta now part of Shire 42
Not applicableStudy completedNCT02593188
What this trial is testing

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Who this might be right for
Primary Immunodeficiency Diseases (PID)
Baxalta now part of Shire 264
Large-scale testing (Phase 3)Study completedNCT00538915
What this trial is testing

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Who this might be right for
Primary Immune Deficiency Disorders (PIDD)
ADMA Biologics, Inc. 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT04554914
What this trial is testing

Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Who this might be right for
Epstein-Barr Virus (EBV)-Associated DiseasesEBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)+8 more
Pierre Fabre Medicament
Not applicableNo Longer AvailableNCT02822495
What this trial is testing

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Who this might be right for
Epstein-Barr Virus (EBV) InfectionsLymphoproliferative DisordersEBV+ Associated Lymphoma+9 more
Atara Biotherapeutics
Not applicableLooking for participantsNCT01222741
What this trial is testing

Studies of Disorders With Increased Susceptibility to Fungal Infections

Who this might be right for
Fungal InfectionsPrimary Immune Deficiencies
National Institute of Allergy and Infectious Diseases (NIAID) 850
Not applicableStudy completedNCT05758506
What this trial is testing

Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan

Who this might be right for
Primary Immunodeficiency Diseases
PATH 200
Large-scale testing (Phase 3)Study completedNCT04842643
What this trial is testing

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

Who this might be right for
Primary Immunodeficiency Disease
Takeda 12
Testing effectiveness (Phase 2)Looking for participantsNCT01962415
What this trial is testing

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Who this might be right for
Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)+4 more
Paul Szabolcs 100
Not applicableStudy completedNCT06150534
What this trial is testing

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

Who this might be right for
Primary Immunodeficiency Diseases (PID)
Takeda 22
Large-scale testing (Phase 3)Study completedNCT00751621
What this trial is testing

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Who this might be right for
Primary Immunodeficiency (PID)
CSL Behring 40
Large-scale testing (Phase 3)Study completedNCT03961009
What this trial is testing

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

Who this might be right for
Primary Immunodeficiency Disease
Kedrion S.p.A. 47
Next Page
190